Core Viewpoint - AbCellera Biologics Inc. reported a quarterly loss of $0.12 per share, outperforming the Zacks Consensus Estimate of a loss of $0.17, indicating a positive earnings surprise of +29.41% [1] Financial Performance - The company posted revenues of $17.08 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 146.95%, compared to $7.32 million in the same quarter last year [2] - Over the last four quarters, AbCellera has surpassed consensus EPS estimates three times [2] Stock Performance - AbCellera shares have increased approximately 40.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] Future Outlook - The company's earnings outlook will be crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.17 on revenues of $7.31 million, and for the current fiscal year, it is -$0.69 on revenues of $25.53 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which AbCellera belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Viewpoint - Kura Oncology reported a significant quarterly loss of $0.75 per share, which was much worse than the Zacks Consensus Estimate of $0.15, indicating a negative earnings surprise of -600.00% [1] Financial Performance - The company posted revenues of $15.29 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 89.23%, compared to zero revenues a year ago [2] - Kura Oncology has surpassed consensus EPS estimates two times over the last four quarters [2] Stock Performance - Kura Oncology shares have declined approximately 30.8% since the beginning of the year, while the S&P 500 has gained 7.9% [3] Future Outlook - The company's earnings outlook will be crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.56 on revenues of $59.35 million, and for the current fiscal year, it is -$1.31 on revenues of $229.86 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Kura Oncology belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Company Performance - Globus Medical reported quarterly earnings of $0.86 per share, exceeding the Zacks Consensus Estimate of $0.76 per share, and up from $0.75 per share a year ago, representing an earnings surprise of +13.16% [1] - The company posted revenues of $745.34 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.49%, and an increase from $629.69 million year-over-year [2] - Over the last four quarters, Globus Medical has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Performance and Outlook - Globus Medical shares have declined approximately 36.1% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $0.81 on revenues of $732.08 million, and for the current fiscal year, it is $3.17 on revenues of $2.84 billion [7] Industry Context - The Medical - Instruments industry, to which Globus Medical belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5]

Core Insights - Pinterest reported quarterly earnings of $0.33 per share, missing the Zacks Consensus Estimate of $0.34 per share, but showing an increase from $0.29 per share a year ago, resulting in an earnings surprise of -2.94% [1] - The company posted revenues of $998.23 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.42% and showing a year-over-year increase from $853.68 million [2] - Pinterest shares have increased approximately 34.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.43 on revenues of $1.02 billion, and for the current fiscal year, it is $1.83 on revenues of $4.16 billion [7] - The estimate revisions trend for Pinterest was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Internet - Software industry, to which Pinterest belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]

Core Viewpoint - VAREX IMAGING reported quarterly earnings of $0.18 per share, significantly exceeding the Zacks Consensus Estimate of $0.04 per share, marking an earnings surprise of +350.00% [1][2] Financial Performance - The company achieved revenues of $203 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.73%, although this represents a decline from year-ago revenues of $209.1 million [2] - Over the last four quarters, VAREX IMAGING has consistently surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - VAREX IMAGING shares have declined approximately 51.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current Zacks Rank for VAREX IMAGING is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $199.03 million, while the estimate for the current fiscal year is $0.42 on revenues of $801.93 million [7] - The trend of estimate revisions for VAREX IMAGING was mixed prior to the earnings release, which may change following the recent results [6] Industry Context - The Medical - Products industry, to which VAREX IMAGING belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Group 1 - Doximity reported quarterly earnings of $0.36 per share, exceeding the Zacks Consensus Estimate of $0.31 per share, and showing an increase from $0.28 per share a year ago, resulting in an earnings surprise of +16.13% [1] - The company achieved revenues of $145.91 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.47%, and up from $126.68 million year-over-year [2] - Doximity has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Group 2 - The stock has gained approximately 8.9% since the beginning of the year, compared to the S&P 500's gain of 7.9% [3] - The future performance of Doximity's stock will largely depend on management's commentary during the earnings call and the outlook for earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.35 on revenues of $150.43 million, and for the current fiscal year, it is $1.46 on revenues of $625.72 million [7] Group 3 - The Medical Info Systems industry, to which Doximity belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Doximity's stock performance [5][6]

Company Performance - Nerdy Inc. reported a quarterly loss of $0.07 per share, better than the Zacks Consensus Estimate of a loss of $0.10, and an improvement from a loss of $0.08 per share a year ago, resulting in an earnings surprise of +30.00% [1] - The company posted revenues of $45.26 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 3.04%, and down from $50.98 million year-over-year [2] - Over the last four quarters, Nerdy has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Future Outlook - The current consensus EPS estimate for the coming quarter is -$0.12 on revenues of $42.34 million, and for the current fiscal year, it is -$0.33 on revenues of $193.8 million [7] - The estimate revisions trend for Nerdy was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Schools industry, to which Nerdy belongs, is currently in the top 15% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% of industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Financial Performance - BioLife Solutions, Inc. (BLFS) reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.02, and improved from a loss of $0.06 per share a year ago, representing an earnings surprise of +100.00% [1] - The company posted revenues of $25.42 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 6.98%, although this is a decline from year-ago revenues of $28.33 million [2] - Over the last four quarters, BioLife Solutions has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance and Outlook - BioLife Solutions shares have declined approximately 18.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $24.55 million, and for the current fiscal year, it is $0.02 on revenues of $97.83 million [7] Industry Context - The Medical - Products industry, to which BioLife Solutions belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5]

Company Performance - Ascend Wellness Holdings, Inc. reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.07, representing an earnings surprise of -71.43% [1] - The company posted revenues of $127.3 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.93% and down from $141.54 million a year ago [2] - Over the last four quarters, the company has only surpassed consensus EPS estimates once and has not beaten consensus revenue estimates [2] Stock Movement and Outlook - Ascend Wellness Holdings, Inc. shares have increased approximately 20.5% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $132.15 million, and for the current fiscal year, it is -$0.27 on revenues of $527.85 million [7] Industry Context - The Medical Services industry, to which Ascend Wellness Holdings, Inc. belongs, is currently ranked in the top 40% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact the stock's performance [5][6]

Core Viewpoint - Prime Medicine, Inc. reported a quarterly loss of $0.41 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.36, representing an earnings surprise of -13.89% [1][2] Financial Performance - The company posted revenues of $1.12 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 59.6%, compared to zero revenues a year ago [2] - Over the last four quarters, Prime Medicine has surpassed consensus EPS estimates only once [2] Stock Performance - Prime Medicine shares have increased by approximately 39.4% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $2.59 million, and for the current fiscal year, it is -$1.30 on revenues of $7.74 million [7] - The estimate revisions trend for Prime Medicine was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Prime Medicine belongs, is currently in the top 41% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8]